KapitallWire – Wall Street is clamoring to get in on the newest Hepatitis C drug stock rally. The move is largely a reaction to a series of successful developments from several new Hepatitis C treatments. The virus currently affects about 170 million people worldwide.
The biopharmaceutical company Gilead Science (GILD) is now leading the race to develop a new all-oral therapy for Hepatitis C after acquiring Pharmasset for $11 billion in November.
